耐性緑膿菌感染症治療薬の世界市場（～2026年）

• 英文タイトル：Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY09080 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は耐性緑膿菌感染症治療薬のグローバル市場について調査・分析したレポートです。種類別（半合成ペニシリン、セファロスポリン、ラクタム薬、その他）市場規模、用途別（病院、クリニック、在宅ケア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別耐性緑膿菌感染症治療薬の競争状況、市場シェア ・世界の耐性緑膿菌感染症治療薬市場：種類別市場規模 2015年-2020年（半合成ペニシリン、セファロスポリン、ラクタム薬、その他） ・世界の耐性緑膿菌感染症治療薬市場：種類別市場規模予測 2021年-2026年（半合成ペニシリン、セファロスポリン、ラクタム薬、その他） ・世界の耐性緑膿菌感染症治療薬市場：用途別市場規模 2015年-2020年（病院、クリニック、在宅ケア） ・世界の耐性緑膿菌感染症治療薬市場：用途別市場規模予測 2021年-2026年（病院、クリニック、在宅ケア） ・北米の耐性緑膿菌感染症治療薬市場分析：米国、カナダ ・ヨーロッパの耐性緑膿菌感染症治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの耐性緑膿菌感染症治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の耐性緑膿菌感染症治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの耐性緑膿菌感染症治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：ContraFect Corp、Inhibrx LP、Achaogen Inc、LegoChem Biosciences Inc、Melinta Therapeutics Inc、Novartis AG、AmpliPhi Biosciences Corp、Biolytics Pharma、Shionogi & Co Ltd ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Resistant Pseudomonas Aeruginosa Infections Drugs Market
The global Resistant Pseudomonas Aeruginosa Infections Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Resistant Pseudomonas Aeruginosa Infections Drugs Scope and Market Size
Resistant Pseudomonas Aeruginosa Infections Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Resistant Pseudomonas Aeruginosa Infections Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Resistant Pseudomonas Aeruginosa Infections Drugs market is segmented into
Semi-Synthetic Penicillin
Cephalosporin
Lactam Drugs
Others

Segment by Application, the Resistant Pseudomonas Aeruginosa Infections Drugs market is segmented into
Hospital
Clinic
Home Care

Regional and Country-level Analysis
The Resistant Pseudomonas Aeruginosa Infections Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Resistant Pseudomonas Aeruginosa Infections Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Resistant Pseudomonas Aeruginosa Infections Drugs Market Share Analysis
Resistant Pseudomonas Aeruginosa Infections Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Resistant Pseudomonas Aeruginosa Infections Drugs business, the date to enter into the Resistant Pseudomonas Aeruginosa Infections Drugs market, Resistant Pseudomonas Aeruginosa Infections Drugs product introduction, recent developments, etc.

The major vendors covered:
ContraFect Corp
Inhibrx LP
Achaogen Inc
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Novartis AG
AmpliPhi Biosciences Corp
Biolytics Pharma
Shionogi & Co Ltd

レポート目次

---

1 Study Coverage
1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Product Introduction
1.2 Market Segments
1.3 Key Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Type
1.4.2 Semi-Synthetic Penicillin
1.4.3 Cephalosporin
1.4.4 Lactam Drugs
1.4.5 Others
1.5 Market by Application
1.5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Home Care
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, Estimates and Forecasts
2.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue 2015-2026
2.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2015-2026
2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Competitor Landscape by Players
3.1 Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers
3.1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers (2015-2020)
3.1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers
3.2.1 Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Resistant Pseudomonas Aeruginosa Infections Drugs Revenue in 2019
3.2.5 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Resistant Pseudomonas Aeruginosa Infections Drugs Price by Manufacturers
3.4 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base Distribution, Product Types
3.4.1 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Resistant Pseudomonas Aeruginosa Infections Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Type (2015-2020)
4.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020)
4.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2015-2020)
4.1.3 Resistant Pseudomonas Aeruginosa Infections Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Resistant Pseudomonas Aeruginosa Infections Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Application (2015-2020)
5.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020)
5.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2015-2020)
5.1.3 Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2015-2020)
5.2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs by Country
6.1.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country
6.1.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Type
6.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Application

7 Europe
7.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs by Country
7.1.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country
7.1.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Type
7.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs by Region
8.1.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region
8.1.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Type
8.3 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Application

9 Latin America
9.1 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs by Country
9.1.1 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country
9.1.2 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Type
9.3 Central & South America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs by Country
10.1.1 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country
10.1.2 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Application

11 Company Profiles
11.1 ContraFect Corp
11.1.1 ContraFect Corp Corporation Information
11.1.2 ContraFect Corp Description and Business Overview
11.1.3 ContraFect Corp Sales, Revenue and Gross Margin (2015-2020)
11.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.1.5 ContraFect Corp Related Developments
11.2 Inhibrx LP
11.2.1 Inhibrx LP Corporation Information
11.2.2 Inhibrx LP Description and Business Overview
11.2.3 Inhibrx LP Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.2.5 Inhibrx LP Related Developments
11.3 Achaogen Inc
11.3.1 Achaogen Inc Corporation Information
11.3.2 Achaogen Inc Description and Business Overview
11.3.3 Achaogen Inc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.3.5 Achaogen Inc Related Developments
11.4 LegoChem Biosciences Inc
11.4.1 LegoChem Biosciences Inc Corporation Information
11.4.2 LegoChem Biosciences Inc Description and Business Overview
11.4.3 LegoChem Biosciences Inc Sales, Revenue and Gross Margin (2015-2020)
11.4.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.4.5 LegoChem Biosciences Inc Related Developments
11.5 Melinta Therapeutics Inc
11.5.1 Melinta Therapeutics Inc Corporation Information
11.5.2 Melinta Therapeutics Inc Description and Business Overview
11.5.3 Melinta Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.5.5 Melinta Therapeutics Inc Related Developments
11.6 Novartis AG
11.6.1 Novartis AG Corporation Information
11.6.2 Novartis AG Description and Business Overview
11.6.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.6.5 Novartis AG Related Developments
11.7 AmpliPhi Biosciences Corp
11.7.1 AmpliPhi Biosciences Corp Corporation Information
11.7.2 AmpliPhi Biosciences Corp Description and Business Overview
11.7.3 AmpliPhi Biosciences Corp Sales, Revenue and Gross Margin (2015-2020)
11.7.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.7.5 AmpliPhi Biosciences Corp Related Developments
11.8 Biolytics Pharma
11.8.1 Biolytics Pharma Corporation Information
11.8.2 Biolytics Pharma Description and Business Overview
11.8.3 Biolytics Pharma Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.8.5 Biolytics Pharma Related Developments
11.9 Shionogi & Co Ltd
11.9.1 Shionogi & Co Ltd Corporation Information
11.9.2 Shionogi & Co Ltd Description and Business Overview
11.9.3 Shionogi & Co Ltd Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.9.5 Shionogi & Co Ltd Related Developments
11.1 ContraFect Corp
11.1.1 ContraFect Corp Corporation Information
11.1.2 ContraFect Corp Description and Business Overview
11.1.3 ContraFect Corp Sales, Revenue and Gross Margin (2015-2020)
11.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
11.1.5 ContraFect Corp Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Estimates and Projections by Region
12.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast (2021-2026)
12.2.2 North America: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Resistant Pseudomonas Aeruginosa Infections Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Resistant Pseudomonas Aeruginosa Infections Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Resistant Pseudomonas Aeruginosa Infections Drugs Market Segments
Table 2. Ranking of Global Top Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Semi-Synthetic Penicillin
Table 5. Major Manufacturers of Cephalosporin
Table 6. Major Manufacturers of Lactam Drugs
Table 7. Major Manufacturers of Others
Table 8. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Resistant Pseudomonas Aeruginosa Infections Drugs as of 2019)
Table 17. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Price (2015-2020) (USD/Pcs)
Table 20. Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
Table 22. Date of International Manufacturers Enter into Resistant Pseudomonas Aeruginosa Infections Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020) (K Pcs)
Table 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Type (2015-2020)
Table 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Type (2015-2020)
Table 28. Resistant Pseudomonas Aeruginosa Infections Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020) (K Pcs)
Table 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Application (2015-2020)
Table 31. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020) (K Pcs)
Table 32. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020) (K Pcs)
Table 36. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020) (K Pcs)
Table 38. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020) (K Pcs)
Table 40. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020) (K Pcs)
Table 44. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020) (K Pcs)
Table 46. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2015-2020) (K Pcs)
Table 48. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020) (K Pcs)
Table 52. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020) (K Pcs)
Table 54. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020) (K Pcs)
Table 56. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020) (K Pcs)
Table 60. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020) (K Pcs)
Table 62. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2015-2020) (K Pcs)
Table 64. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2015-2020) (K Pcs)
Table 68. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2015-2020) (K Pcs)
Table 70. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
Table 71. ContraFect Corp Corporation Information
Table 72. ContraFect Corp Description and Major Businesses
Table 73. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 74. ContraFect Corp Product
Table 75. ContraFect Corp Recent Development
Table 76. Inhibrx LP Corporation Information
Table 77. Inhibrx LP Description and Major Businesses
Table 78. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. Inhibrx LP Product
Table 80. Inhibrx LP Recent Development
Table 81. Achaogen Inc Corporation Information
Table 82. Achaogen Inc Description and Major Businesses
Table 83. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Achaogen Inc Product
Table 85. Achaogen Inc Recent Development
Table 86. LegoChem Biosciences Inc Corporation Information
Table 87. LegoChem Biosciences Inc Description and Major Businesses
Table 88. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. LegoChem Biosciences Inc Product
Table 90. LegoChem Biosciences Inc Recent Development
Table 91. Melinta Therapeutics Inc Corporation Information
Table 92. Melinta Therapeutics Inc Description and Major Businesses
Table 93. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. Melinta Therapeutics Inc Product
Table 95. Melinta Therapeutics Inc Recent Development
Table 96. Novartis AG Corporation Information
Table 97. Novartis AG Description and Major Businesses
Table 98. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 99. Novartis AG Product
Table 100. Novartis AG Recent Development
Table 101. AmpliPhi Biosciences Corp Corporation Information
Table 102. AmpliPhi Biosciences Corp Description and Major Businesses
Table 103. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 104. AmpliPhi Biosciences Corp Product
Table 105. AmpliPhi Biosciences Corp Recent Development
Table 106. Biolytics Pharma Corporation Information
Table 107. Biolytics Pharma Description and Major Businesses
Table 108. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 109. Biolytics Pharma Product
Table 110. Biolytics Pharma Recent Development
Table 111. Shionogi & Co Ltd Corporation Information
Table 112. Shionogi & Co Ltd Description and Major Businesses
Table 113. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 114. Shionogi & Co Ltd Product
Table 115. Shionogi & Co Ltd Recent Development
Table 116. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 117. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 118. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 119. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 120. North America: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 121. North America: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 122. Europe: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 123. Europe: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 124. Asia Pacific: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 125. Asia Pacific: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 126. Latin America: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 127. Latin America: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 128. Middle East and Africa: Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 129. Middle East and Africa: Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 130. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 131. Key Challenges
Table 132. Market Risks
Table 133. Main Points Interviewed from Key Resistant Pseudomonas Aeruginosa Infections Drugs Players
Table 134. Resistant Pseudomonas Aeruginosa Infections Drugs Customers List
Table 135. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors List
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
List of Figures
Figure 1. Resistant Pseudomonas Aeruginosa Infections Drugs Product Picture
Figure 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Semi-Synthetic Penicillin Product Picture
Figure 4. Cephalosporin Product Picture
Figure 5. Lactam Drugs Product Picture
Figure 6. Others Product Picture
Figure 7. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Home Care
Figure 11. Resistant Pseudomonas Aeruginosa Infections Drugs Report Years Considered
Figure 12. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2015-2026 (K Pcs)
Figure 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region in 2019
Figure 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region in 2019
Figure 19. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Resistant Pseudomonas Aeruginosa Infections Drugs Revenue in 2019
Figure 21. Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type in 2019
Figure 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type in 2019
Figure 26. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application in 2019
Figure 29. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application in 2019
Figure 31. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 32. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2019
Figure 34. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 36. U.S. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type in 2019
Figure 40. North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Application in 2019
Figure 41. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2019
Figure 44. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type in 2019
Figure 56. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 58. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region in 2019
Figure 61. China Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Indonesia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Thailand Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Malaysia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Philippines Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Vietnam Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Application in 2019
Figure 85. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 86. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 90. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type in 2019
Figure 96. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 98. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 102. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. U.A.E Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Application in 2019
Figure 109. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 110. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed

---